BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen VL, Yeh ML, Yang JD, Leong J, Huang DQ, Toyoda H, Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu Q, Dan YY, Schwartz M, Roberts LR, Yu ML, Nguyen MH. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. Hepatol Commun 2021;5:122-32. [PMID: 33437906 DOI: 10.1002/hep4.1606] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Cavalcante LN, Dezan MGF, Paz CLDSL, Lyra AC. RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Arq Gastroenterol 2022. [DOI: 10.1590/s0004-2803.202204000-93] [Reference Citation Analysis]
2 Tsai PC, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Chen CY, Yu ML; T-COACH Study Group. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol 2022:S0168-8278(22)03129-4. [PMID: 36208843 DOI: 10.1016/j.jhep.2022.09.019] [Reference Citation Analysis]
3 Jang TY, Dai CY. Cutoff values of protein induced by vitamin K absence or antagonist II for diagnosing hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e30936. [PMID: 36181046 DOI: 10.1097/MD.0000000000030936] [Reference Citation Analysis]
4 Xie X, Zheng M, Guo W, Zhou Y, Xiang Z, Li Y, Yang J. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma. Sci Rep 2022;12:13969. [PMID: 35978032 DOI: 10.1038/s41598-022-18197-6] [Reference Citation Analysis]
5 Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, Tan DJH, Lim WH, Lin SY, Huang D, Chan M, Khoo CM, Chew NWS, Kaewdech A, Chamroonkul N, Dan YY, Noureddin M, Muthiah M, Eslam M, Ng CH. Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals. J Clin Endocrinol Metab 2022:dgac321. [PMID: 35587339 DOI: 10.1210/clinem/dgac321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
6 Zhu C, Huang D, Ma H, Qian C, You H, Bu L, Qu S. High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. Front Endocrinol 2022;13:848937. [DOI: 10.3389/fendo.2022.848937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zheng Q, Xue C, Gu X, Shan D, Chu Q, Wang J, Zhu H, Chen Z. Multi-Omics Characterizes the Effects and Mechanisms of CD1d in Nonalcoholic Fatty Liver Disease Development. Front Cell Dev Biol 2022;10:830702. [DOI: 10.3389/fcell.2022.830702] [Reference Citation Analysis]